Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1966]

Update from KAITLIN for high-risk HER2-positive early breast cancer

Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA

Update from KAITLIN for high-risk HER2-positive early breast cancer ( Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA )

Cisplatin plus/minus veliparib in metastatic TNBC and/or germline BRCA...

Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA

Cisplatin plus/minus veliparib in metastatic TNBC and/or germline BRCA-associated breast cancer ( Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA )

Better genetic diagnostics in Ugandan breast cancer patients

Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA

Better genetic diagnostics in Ugandan breast cancer patients ( Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA )

COVID-19: Treating breast cancer and the knock on effects of the coronavirus...

Prof Stephen Johnston - Royal Marsden NHS Foundation Trust, London, UK

COVID-19: Treating breast cancer and the knock on effects of the coronavirus pandemic ( Prof Stephen Johnston - Royal Marsden NHS Foundation Trust, London, UK )

Pembrolizumab plus chemotherapy for patients with metastatic triple-negative...

Dr Javier Cortés - IOB Institute of Oncology, Madrid and Barcelona, Spain

Pembrolizumab plus chemotherapy for patients with metastatic triple-negative breast cancer ( Dr Javier Cortés - IOB Institute of Oncology, Madrid and Barcelona, Spain )

COM701 as a monotherapy and in combination with nivolumab for various advanced...

Dr. Ecaterina Dumbrava - MD Anderson Cancer Centre, Houston, USA

COM701 as a monotherapy and in combination with nivolumab for various advanced solid tumours ( Dr. Ecaterina Dumbrava - MD Anderson Cancer Centre, Houston, USA )

Do immune checkpoint inhibitors work in EGFR mutant lung cancer?

Dr Edward Garon - UCLA Medical Center, Santa Monica, USA

Do immune checkpoint inhibitors work in EGFR mutant lung cancer? ( Dr Edward Garon - UCLA Medical Center, Santa Monica, USA )

COVID-19: Using oncology drugs and surgery during the coronavirus pandemic

Dr. Paolo Ascierto - Istituto Nazionale Tumori, Milan, Italy

COVID-19: Using oncology drugs and surgery during the coronavirus pandemic ( Dr. Paolo Ascierto - Istituto Nazionale Tumori, Milan, Italy )

IMPRIME 1: Combination of pembrolizumab and a novel innate immune activator...

Dr Steven O'Day - John Wayne Cancer Institute, Santa Monica, USA

IMPRIME 1: Combination of pembrolizumab and a novel innate immune activator, Imprime PGG, in second-line mTNBC ( Dr Steven O'Day - John Wayne Cancer Institute, Santa Monica, USA )

COVID-19: Management of non-small cell lung cancer patients during the...

Dr Heather Wakelee - Stanford University, Stanford, USA

COVID-19: Management of non-small cell lung cancer patients during the coronavirus pandemic ( Dr Heather Wakelee - Stanford University, Stanford, USA )

Managing toxicities associated with immune-checkpoint inhibitors

Prof Olivier Lambotte - Hôpitaux de Paris, Paris, France

Managing toxicities associated with immune-checkpoint inhibitors ( Prof Olivier Lambotte - Hôpitaux de Paris, Paris, France )

I-SPY 2: Durvalumab in combination with olaparib and paclitaxel in high-risk...

Prof Lajos Pusztai - Yale Cancer Center, New Haven, USA

I-SPY 2: Durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer ( Prof Lajos Pusztai - Yale Cancer Center, New Haven, USA )

More from ecancer